CEL-SCI (CVM) Competitors $2.29 -0.11 (-4.58%) As of 06/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CVM vs. GRCE, MRNS, MAAQ, ALLK, SXTC, INKT, RANI, SCYX, DYAI, and FBLGShould you be buying CEL-SCI stock or one of its competitors? The main competitors of CEL-SCI include Grace Therapeutics (GRCE), Marinus Pharmaceuticals (MRNS), Mana Capital Acquisition (MAAQ), Allakos (ALLK), China SXT Pharmaceuticals (SXTC), MiNK Therapeutics (INKT), Rani Therapeutics (RANI), SCYNEXIS (SCYX), Dyadic International (DYAI), and FibroBiologics (FBLG). These companies are all part of the "pharmaceutical products" industry. CEL-SCI vs. Its Competitors Grace Therapeutics Marinus Pharmaceuticals Mana Capital Acquisition Allakos China SXT Pharmaceuticals MiNK Therapeutics Rani Therapeutics SCYNEXIS Dyadic International FibroBiologics Grace Therapeutics (NASDAQ:GRCE) and CEL-SCI (NYSE:CVM) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment. Is GRCE or CVM more profitable? Grace Therapeutics' return on equity of -19.45% beat CEL-SCI's return on equity.Company Net Margins Return on Equity Return on Assets Grace TherapeuticsN/A -19.45% -16.99% CEL-SCI N/A -238.05%-104.65% Do insiders and institutionals have more ownership in GRCE or CVM? 6.1% of Grace Therapeutics shares are held by institutional investors. Comparatively, 12.1% of CEL-SCI shares are held by institutional investors. 13.5% of Grace Therapeutics shares are held by insiders. Comparatively, 9.9% of CEL-SCI shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has better valuation & earnings, GRCE or CVM? Grace Therapeutics is trading at a lower price-to-earnings ratio than CEL-SCI, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGrace TherapeuticsN/AN/A-$9.57M-$1.16-2.56CEL-SCIN/AN/A-$26.92M-$12.61-0.18 Does the media favor GRCE or CVM? In the previous week, Grace Therapeutics had 5 more articles in the media than CEL-SCI. MarketBeat recorded 6 mentions for Grace Therapeutics and 1 mentions for CEL-SCI. CEL-SCI's average media sentiment score of 0.71 beat Grace Therapeutics' score of 0.61 indicating that CEL-SCI is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grace Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CEL-SCI 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate GRCE or CVM? Grace Therapeutics presently has a consensus price target of $12.00, suggesting a potential upside of 304.04%. Given Grace Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Grace Therapeutics is more favorable than CEL-SCI.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Grace Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00CEL-SCI 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility & risk, GRCE or CVM? Grace Therapeutics has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Comparatively, CEL-SCI has a beta of 0.27, meaning that its stock price is 73% less volatile than the S&P 500. SummaryGrace Therapeutics beats CEL-SCI on 11 of the 13 factors compared between the two stocks. Get CEL-SCI News Delivered to You Automatically Sign up to receive the latest news and ratings for CVM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CVM vs. The Competition Export to ExcelMetricCEL-SCIBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$6.94M$199.88M$5.45B$20.29BDividend YieldN/AN/A5.36%3.76%P/E Ratio-4.77N/A26.3927.49Price / SalesN/A276.79406.9538.27Price / CashN/A22.4425.8817.85Price / Book15.275.447.924.54Net Income-$26.92M-$96.61M$3.15B$985.09M7 Day Performance-5.76%2.11%0.66%0.86%1 Month Performance9.05%4.37%4.95%4.02%1 Year Performance-93.18%16.25%32.31%13.26% CEL-SCI Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CVMCEL-SCI0.2007 of 5 stars$2.29-4.6%N/A-93.4%$6.94MN/A-4.7743GRCEGrace Therapeutics2.3663 of 5 stars$2.93-2.3%$12.00+309.6%N/A$30.42MN/A-2.53N/AHigh Trading VolumeMRNSMarinus Pharmaceuticals2.2601 of 5 stars$0.55-0.2%$3.92+613.3%-53.1%$30.32M$30.99M-0.22110MAAQMana Capital AcquisitionN/A$3.71-4.6%N/A+556.4%$30.14MN/A0.001ALLKAllakos2.7996 of 5 stars$0.33flat$2.00+507.7%N/A$29.74MN/A-0.16190SXTCChina SXT Pharmaceuticals0.4706 of 5 stars$1.84flatN/A-80.2%$29.12M$1.93M0.0090INKTMiNK Therapeutics3.3612 of 5 stars$7.48+3.0%$37.50+401.3%-22.7%$28.94MN/A-2.9730Positive NewsRANIRani Therapeutics2.2103 of 5 stars$0.49-2.1%$7.33+1,396.6%-86.5%$28.77M$1.03M-0.49110Positive NewsGap DownSCYXSCYNEXIS0.9199 of 5 stars$0.73-0.6%N/A-66.3%$28.65M$3.75M-1.3060Positive NewsDYAIDyadic International2.5737 of 5 stars$0.94+2.9%$6.00+539.7%-33.1%$27.44M$3.49M-4.697Gap UpFBLGFibroBiologics2.9359 of 5 stars$0.72+3.6%$13.00+1,703.3%-87.5%$26.61MN/A-3.4310Gap Up Related Companies and Tools Related Companies Grace Therapeutics Competitors Marinus Pharmaceuticals Competitors Mana Capital Acquisition Competitors Allakos Competitors China SXT Pharmaceuticals Competitors MiNK Therapeutics Competitors Rani Therapeutics Competitors SCYNEXIS Competitors Dyadic International Competitors FibroBiologics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CVM) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredGold prediction: $5,000/oz. or higher is comingThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredNvidia’s Huang: AI is going to need 100x more power12Nvidia CEO Jensen Huang didn't mince words. After Nvidia's latest earnings call, Huang said AI now requires...Weiss Ratings | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CEL-SCI Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share CEL-SCI With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
